Clinical trials: Digestive Cancer
Metastatic Pancreatic Cancer
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
This randomized, Phase 2, open label study aims to assess the efficacy and safety of gemcitabine + nab paclitaxel with or without dociparstat (ODSH) as first line treatment of metastatic pancreatic cancer.
- Trial name
- PGPC1 (NCT01461915)
- Testing
- Nab paclitaxel, Gemcitabine, Dociparstat
- Where
- 16 sites in United States
- Volunteers
- 60 people
- Sponsor
- Jazz Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to…
- Trial name
- RELIANT (NCT04329949)
- Testing
- Relacorilant, 100 mg and 25 mg, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 43 people
- Sponsor
- Corcept Therapeutics
Carcinogenic Fatigue
Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Patients(BCS) With Digestive Tract .
The efficacy and safety of cancer patients in patients with gastrointestinal cancer (Palliative care) in patients with gastrointestinal tumor (chemotherapy) were prospectively, randomized blind, multicenter clinical trials.
- Trial name
- NCT03456609
- Testing
- shenqifuzheng injection, Sodium Chloride Injection 0.9%
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Non-Small Cell Lung Cancer, Colorectal Cancer
Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
An interventional, prospective clinical performance study protocol, for the testing of DNA extracted from tumor tissue biopsy samples, using the therascreen® KRAS RGQ PCR Kit, from patients with Non-Small Cell Lung Cancer and…
- Trial name
- NCT05348187
- Testing
- therascreen® KRAS RGQ PCR Kit
- Where
- United Kingdom
- Volunteers
- 309 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Carcinoma, Hepatocellular
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
CC-122-HCC-001 is a Phase 1b dose escalation and expansion clinical study of CC-122 in combination with sorafenib for subjects with unresectable HCC who have received no prior systemic therapy for HCC.
- Trial name
- NCT02323906
- Testing
- CC-122, Sorafenib
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Celgene
Cancer, Pain
A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain
The purpose of this study is to test the oxycodone/naloxone combination compared to oxycodone alone in patient's specific type of "chronic cancer pain".
- Conditions
- Cancer, Pain, Constipation
- Trial name
- NCT00513656
- Testing
- Oxycodone, Oxycodone/Naloxone
- Where
- United Kingdom
- Volunteers
- 230 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Carcinoma
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant…
- Trial name
- EVOLVE-1 (NCT01035229)
- Testing
- Everolimus, Best Supportive Care (BSC)
- Where
- 131 sites in United States, Australia and 16 more
- Volunteers
- 546 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Cancer
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo…
- Trial name
- SKYSCRAPER-08 (NCT04540211)
- Testing
- Atezolizumab, Tiragolumab, Paclitaxel
- Where
- 67 sites in China, Hong Kong and 3 more
- Volunteers
- 461 people
- Sponsor
- Hoffmann-La Roche
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Breast Cancer
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02784795
- Testing
- LY3039478, Taladegib, Abemaciclib
- Where
- 11 sites in United States, Denmark and 2 more
- Volunteers
- 94 people
- Sponsor
- Eli Lilly and Company
Cancer of the Liver
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population.
- Trial name
- NCT00422877
- Testing
- Taxoprexin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- American Regent, Inc.
Colorectal Cancer
Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)
The purpose of this study is to determine whether S-1 and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer
- Trial name
- NCT00569699
- Testing
- S-1, Bevacizumab
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Colorectal Cancer
Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia
To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies.
- Trial name
- TERRA (NCT01955837)
- Testing
- TAS-102
- Where
- 4 sites in China, South Korea and 1 more
- Volunteers
- 406 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Nausea Post Chemotherapy, Vomiting
Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC
Study based on the pharmacokinetic, pharmacodynamic, safety and stability evaluation of 3 standardized formulations of THC, to be used in healthy volunteers and post-chemotherapy patients as an adjuvant in the symptomatic…
- Conditions
- Nausea Post Chemotherapy, Vomiting, Cancer Pain, Cancer Related Pain
- Trial name
- NCT05272865
- Testing
- Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator
- Where
- Colombia
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- LaSanta S A S
Gastrointestinal Cancer, Metastatic
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
This study is open to adults with advanced colorectal cancer or with advanced pancreatic cancer. The study has 2 parts. In the first part, participants with colorectal cancer get a medicine called BI 905711 combined with…
- Trial name
- NCT05087992
- Testing
- BI 905711, FOLFIRI, Bevacizumab
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
This is a study of pembrolizumab (MK-3475) for advanced gastric or gastroesophageal junction adenocarcinoma; pembrolizumab will be given as monotherapy to participants who have had previous treatment or who are treatment-naïve…
- Trial name
- NCT02335411
- Testing
- pembrolizumab, cisplatin, 5-FU
- Volunteers
- 318 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the ATU.
- Trial name
- NCT02307812
- Testing
- Ramucirumab, Paclitaxel
- Sponsor
- Eli Lilly and Company
Barrett Esophagus, Esophageal Adenocarcinoma
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or…
- Conditions
- Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
- Trial name
- ESOGUARDBE2 (NCT04295811)
- Testing
- EsoGuard (lab assay), Esophagogastroduodenoscopy
- Where
- 35 sites in United States, Netherlands
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Lucid Diagnostics, Inc.
Stomach Neoplasms
An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy
The study consisted of two parts. In Part 1 the study enrolled 38 patients (Step 1 Simon 2 step design) after which Step 2 was opened and the total enrollment target for the study (n=63) was exceeded due to a rapid enrollment (78…
- Trial name
- NCT00226811
- Testing
- Sunitinib
- Where
- 18 sites in China, Hong Kong and 5 more
- Volunteers
- 78 people
- Sponsor
- Pfizer
Carcinoma, Hepatocellular
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
This is a Phase IIIb, one arm, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab + bevacizumab in patients with unresectable HCC who have received no prior systemic treatment.
- Trial name
- AMETHISTA (NCT04487067)
- Testing
- Atezolizumab, Bevacizumab
- Where
- 21 sites in Italy
- Volunteers
- 152 people
- Sponsor
- Hoffmann-La Roche